Electra Therapeutics Prices $350M IPO at $15/Share, Lists on Nasdaq as ETRA
ETRA is trading near its 52-week low of $13.25 (1.8% above the low).
Summary
Electra Therapeutics priced its IPO at $15.00 per share, raising $350 million in gross proceeds to fund its lead drug candidate ipsoprubart through pivotal trials. The stock lists on Nasdaq as 'ETRA' with trading expected September 21, 2026.
Key Events · Financing and Capital Events · ETRA
-
IPO Priced at $15.00 Per Share
Electra Therapeutics priced 23,333,334 shares at $15.00 each for gross proceeds of $350,000,010. Underwriters Jefferies, TD Cowen, Evercore ISI, and Cantor will receive $1.05 per share in discounts, leaving the company with $325.5 million before expenses.
-
Net Proceeds of $319.9 Million
After underwriting discounts of $24.5 million and estimated offering expenses of $5.65 million, Electra will net approximately $319.9 million. A 30-day underwriter option for 3.5 million additional shares could add up to $48.8 million more.
-
Going Concern Resolved by Offering
The company's auditor included a going concern explanatory paragraph, noting substantial doubt about Electra's ability to continue without additional capital. The IPO proceeds, combined with existing cash of $97.7 million, extend the runway into 2029.
-
Use of Proceeds Focused on Ipsoprubart
Approximately $220 million will fund the Phase 2/3 SURPASS registrational trial of ipsoprubart in sHLH through topline results and BLA submission. An additional $25 million goes to T/NK cell malignancy development and $50 million to ELA822.
Analysis · ETRA · Life Sciences
Electra Therapeutics finalized its initial public offering, pricing 23.3 million shares at $15.00 each for gross proceeds of $350 million. The company will net approximately $319.9 million after underwriting discounts and expenses, with shares expected to begin trading on the Nasdaq Global Select Market under ticker 'ETRA' on September 21, 2026. This capital raise is critical for the clinical-stage biotech, which had only $97.7 million in cash as of June 30, 2026 and carried a going concern warning from its auditor. The proceeds extend the company's cash runway into 2029, funding the Phase 2/3 registrational trial of lead candidate ipsoprubart in sHLH through topline results and BLA submission. The offering prices at $15.00 per share, above the current trading price of $13.49, though the stock has not yet begun public trading. Existing shareholders face immediate dilution of $8.47 per share, with new investors owning 37.2% of the company post-offering.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.9% of the 1009 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ETRA was trading at $13.49 on NASDAQ in the Life Sciences sector. The 52-week trading range was $13.25 to $15.50. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.